Yousif Capital Management LLC Has $340,000 Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Yousif Capital Management LLC cut its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 2.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,059 shares of the company’s stock after selling 446 shares during the period. Yousif Capital Management LLC’s holdings in Pacira BioSciences were worth $340,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its stake in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after buying an additional 2,749 shares in the last quarter. Virtus Investment Advisers Inc. acquired a new stake in shares of Pacira BioSciences in the 3rd quarter valued at approximately $98,000. CWM LLC grew its holdings in shares of Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after purchasing an additional 5,716 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock worth $134,000 after purchasing an additional 3,404 shares in the last quarter. Finally, Quest Partners LLC lifted its stake in Pacira BioSciences by 137.6% in the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock valued at $142,000 after purchasing an additional 5,449 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

PCRX has been the subject of several research analyst reports. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price target for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays reduced their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a report on Wednesday, December 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Pacira BioSciences has an average rating of “Hold” and an average target price of $22.78.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $25.44 on Tuesday. The firm has a 50 day moving average of $22.00 and a 200-day moving average of $18.13. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -12.53 and a beta of 0.80. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.